Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Portopulmonary Hypertension
NCT01224210Phase 3Completed
- Sponsor
- Tufts Medical Center
- Start
- Mar 2010
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambrisentan in portopulmonary hypertension (POPH), sponsored by Tufts Medical Center. Primary endpoints: Pulmonary Vascular Resistance at 24 weeks and 6 Minute Walk Distance at 24 weeks. Started Mar 2010; status: completed.
02
Drugs
ambrisentan
03
Conditions
portopulmonary hypertension (POPH)
Beyond the preview
Go deeper on NCT01224210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224210.